Protara Therapeutics, Inc. $TARA Shares Bought by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. raised its holdings in Protara Therapeutics, Inc. (NASDAQ:TARA) by 84.1% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 567,621 shares of the company’s stock after buying an additional 259,287 shares during the period. Assenagon Asset Management S.A. owned approximately 1.05% of Protara Therapeutics worth $2,957,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Virtu Financial LLC purchased a new stake in shares of Protara Therapeutics during the fourth quarter worth $368,000. ADAR1 Capital Management LLC boosted its holdings in Protara Therapeutics by 3,127.4% in the fourth quarter. ADAR1 Capital Management LLC now owns 1,136,799 shares of the company’s stock valued at $6,059,000 after purchasing an additional 1,101,576 shares during the period. XTX Topco Ltd purchased a new position in Protara Therapeutics in the fourth quarter valued at $615,000. Sphera Funds Management LTD. acquired a new position in Protara Therapeutics during the 4th quarter worth $3,464,000. Finally, Quadrature Capital Ltd grew its stake in Protara Therapeutics by 39.4% during the 4th quarter. Quadrature Capital Ltd now owns 24,184 shares of the company’s stock worth $129,000 after purchasing an additional 6,838 shares in the last quarter. Hedge funds and other institutional investors own 38.13% of the company’s stock.

Protara Therapeutics Trading Down 8.2%

Shares of TARA stock opened at $3.82 on Wednesday. The company has a market cap of $214.68 million, a P/E ratio of -2.85 and a beta of 1.45. The firm has a fifty day moving average price of $4.62 and a 200 day moving average price of $5.34. Protara Therapeutics, Inc. has a 12 month low of $2.77 and a 12 month high of $7.82.

Protara Therapeutics (NASDAQ:TARA) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.05. On average, equities analysts forecast that Protara Therapeutics, Inc. will post -1.44 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Protara Therapeutics in a research report on Wednesday, May 20th. Wall Street Zen upgraded Protara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. TD Cowen reissued a “buy” rating on shares of Protara Therapeutics in a research report on Tuesday, March 10th. HC Wainwright restated a “buy” rating on shares of Protara Therapeutics in a research note on Wednesday, May 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Protara Therapeutics in a report on Tuesday, April 21st. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $26.25.

Protara Therapeutics Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.